Neoleukin Therapeutics (NASDAQ: NLTX) is one of 603 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Neoleukin Therapeutics to related companies based on the strength of its profitability, earnings, analyst recommendations, institutional ownership, valuation, risk and dividends.
Institutional & Insider Ownership
38.8% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 45.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 4.0% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 15.9% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Neoleukin Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Neoleukin Therapeutics||$25.00 million||-$31.58 million||-8.25|
|Neoleukin Therapeutics Competitors||$2.20 billion||$283.83 million||-4.07|
Neoleukin Therapeutics’ competitors have higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Neoleukin Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Neoleukin Therapeutics Competitors||-2,565.03%||-250.43%||-31.41%|
Risk & Volatility
Neoleukin Therapeutics has a beta of -6.92, meaning that its share price is 792% less volatile than the S&P 500. Comparatively, Neoleukin Therapeutics’ competitors have a beta of 1.88, meaning that their average share price is 88% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for Neoleukin Therapeutics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Neoleukin Therapeutics Competitors||6181||16714||32700||1301||2.51|
Neoleukin Therapeutics presently has a consensus target price of $20.00, suggesting a potential upside of 80.83%. As a group, “Pharmaceutical preparations” companies have a potential upside of 37.43%. Given Neoleukin Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Neoleukin Therapeutics is more favorable than its competitors.
Neoleukin Therapeutics competitors beat Neoleukin Therapeutics on 7 of the 13 factors compared.
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies using protein design technology. The company's lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.